Search

Displaying results 2741 - 2750 of 10000 in total
  1. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive … It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.

  2. Drug

    Malathion

    go.drugbank.com/drugs/DB00772
    Approved

    Malathion is an irreversible cholinesterase inhibitor and has low human toxicity. … Malathion is a parasympathomimetic organophosphate compound that is used as an insecticide for the treatment of head lice.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Pilocarpine

    go.drugbank.com/drugs/DB01085
    ApprovedInvestigational

    [A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors.

    Mixtures: E-pilo-2 Oph Soln, E-pilo-6 Oph Soln
  4. Drug

    Tigecycline

    go.drugbank.com/drugs/DB00560
    ApprovedInvestigational

    Food and Drug Administration (FDA) on June 17, 2005. … It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S.

  5. Drug

    Fluocinolone acetonide

    go.drugbank.com/drugs/DB00591
    ApprovedInvestigationalVet approved

    [T357] It has been used extensively in dermatological preparations and it has also been investigated thoroughly for its use in implantable corticosteroid devices. … [T358] This type of device containing fluocinolone acetonide was developed by Taro Pharmaceuticals and approved by FDA in May 2016.[L4676]

    Mixtures: OCIDERM-N, CINOLON-N
  6. Drug

    Factor XIII (human)

    go.drugbank.com/drugs/DB12909
    ApprovedInvestigational

    Compared to Factor XIII (human), which is purified from pooled human plasma, [DB09310] is produced through recombinant DNA technology where the target protein is grown in yeast and then isolated [FDA Label … Factor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation

  7. Drug

    Succinylcholine

    go.drugbank.com/drugs/DB00202
    ApprovedInvestigational

    [A19054] It has been widely used for over 50 years,[A299] most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and surgical procedures. … Its rapid onset and offset, with effects beginning within 60 seconds of intravenous administration and lasting between four to six minutes, make succinylcholine particularly useful in the setting of short

    Synonyms: 2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)Products: Suxamethonium Aguettant 10 mg/ml Injektionslösung in einer Fertigspritze
  8. Drug

    Triflupromazine

    go.drugbank.com/drugs/DB00508
    ApprovedVet approved

    A phenothiazine used as an antipsychotic agent and as an antiemetic.

  9. Drug

    Miltefosine

    go.drugbank.com/drugs/DB09031
    ApprovedInvestigational

    Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. … It can be administered topically or orally and is only indicated in patients aged 12 years or older.

  10. Drug

    Carfilzomib

    go.drugbank.com/drugs/DB08889
    ApprovedInvestigational

    Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. … FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]